Testosterone replacement therapy in hypogonadal men following prostate cancer treatment: A questionnaire-based retrospective study among urologists in Bavaria, Germany - Abstract

Background: Several reports suggest testosterone replacement therapy (TRT) may be an option in selected hypogonadal patients with a history of prostate cancer (PCa) and no evidence of disease after curative treatment.

Our aim was to assess TRT experience and patient management among urologists in Bavaria.

Materials and Methods: Questionnaires were developed and mailed to all registered urologists in Bavaria (n = 420) regarding their experience with TRT in patients with treated PCa.

Results: One hundred and ninety-three (46%) urologists returned the questionnaire and reported their experience with TRT in hypogonadal patients after curative treatment for PCa. Complete data was available for 32 men. Twenty-six patients (81%) received TRT after prostatectomy, 1 patient after external beam radiation, 3 patients after high-dose brachytherapy and 2 patients after high-intensity focused ultrasound. Of the PCa cases, 88.5% (23/26) were organ confined (pT2a-c), and 3 were pT3 tumors. All patients were pN0/cN0, and only 1 patient (pT3a) had a positive surgical margin status postoperatively. After a mean follow-up of 39.8 months, no biochemical relapse was observed.

Conclusion: To date, there is no clear evidence to withhold TRT from hypogonadal men after curative PCa treatment. Our findings, although with limitations, fit in with the available data showing that TRT does not put patients at an increased risk after curative treatment of PCa.

Written by:
Kühn CM, Strasser H, Romming A, Wullich B, Goebell PJ.   Are you the author?
Department of Urology, Friedrich Alexander University Erlangen-Nürnberg, Erlangen, Germany.

Reference: Urol Int. 2015 Feb 10. Epub ahead of print.
doi: 10.1159/000371725

PubMed Abstract
PMID: 25677365

UroToday.com Androgen Deficiency Section